Clinical effectiveness of magnesium orotate in patients with cardiac arrhythmias, arterial hypertension, and mitral valve prolapse
Abstract
Aim. To evaluate the effectiveness of magnesium orotate in the patients with cardiac arrhythmias, arterial hypertension (AH), and idiopathic mitral valve prolapse (MVP).
Material and methods. The complex examination, dynamic follow-up, and placebo-controlled differentiated treatment were performed in 84 patients with idiopathic MVP. All participants underwent echocardiography, 24-hour blood pressure monitoring (BPM) and electrocardiography (ECG) monitoring, office BP measurement, spectral analysis of heart rate variability (HRV), and physical stress test. The main group (MG; n=43) received magnesium orotate (3000 mg/d) for 6 months; the comparison group (CG; n=41) received placebo.
Results. According to the 24-hour ECG monitoring data, the treatment was associated with disappearance of high-grade arrhythmias and a 40% reduction in supraventricular (paroxysmal and non-paroxysmal) tachycardia incidence. The number of ventricular extrasystoles was reduced in 26%, and they disappeared in 54%. In 8%, polytopic ventricular extrasystoles were substituted by occasional monotopic extrasystoles. These changes were not observed in the CG patients. The percentage of Stage I AH patients decreased from 38% to 8% in the MG, and from 30% to 20% in the CG.
Conclusion. In MVP patients, magnesium orotate treatment improved electro-physiological heart parameters, with reduced supraventricular and ventricular extrasystole incidence and improved circadian BP profile.
About the Authors
E. V. Akatova
Moscow State Medico-Stomatological University
Russian Federation
Moscow
Russian Federation
Moscow
O. P. Nikolin
Moscow State Medico-Stomatological University
Russian Federation
Moscow
Russian Federation
Moscow
A. I. Martynov
Moscow State Medico-Stomatological University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Городецкий В.В., Талибов О.Б. Препараты магния в медицинской практике. Малая энциклопедия магния. Москва “Медпрактика” 2003; 44 с.
2. Громова О.А. Магний и пиридоксин: основы знаний. Новые технологии диагностики и коррекции дефицита магния. Москва: РСЦ Институт микроэлементов, ЮНЕСКО 2006; 176 с.
3. Мартынов А.И., Степура О.Б., Остроумова О.Д. и др. Пролапс митрального клапана. Часть II. Нарушения ритма и психологический статус. Кардиология 1998; 38(2): 74-81.
4. Степура О.Б., Остроумова О.Д. и др. Роль магния в патогенезе и развитии клинической симптоматики у лиц с идиопатическим пролапсом митрального клапана. РКЖ 1998; 3: 45-7.
5. Степура О.Б., Мельник О.О., Шехтер А.Б. и др. Результаты применения магниевой соли оротовой кислоты “Магнерот” при лечении больных с идиопатическим пролапсом митрального клапана. Росс мед вести 1999; 2: 12-6.
6. Степура О.Б. Синдром дисплазии соединительной ткани сердца. Автореф дисс докт мед наук. Москва 1995.
7. Сторожаков Г.И., Копелев А.М., Царева Л.А. О внезапной смерти при пролапсе митрального клапана. Тер архив 1989; 61(4): 135-7.
8. Dreosti E. Magnesium status and health. Nutr Rev 1995; 53: 23-7.
9. Coghlan HC, Natello G. Erythrocyte magnesium in symptomatic patients with primary mitral valve prolapse: relationship to symptoms, mitral leaflet thickness, joint hypermobility and autonomic regulation. Magnes-Trace-Elem 1991–92; 10(2-4): 205-14.
10. Cohen L, Bittermann H, Grenadier E, et al. Idiopathic magnesium deficiency in mitral valve prolapse. Am J Cardiol 1986; 57(6): 486-7.
11. Kitlinski M, Konduracka E, Piwowarska. Evaluation of magnesium cation levels in serum of patients with mitral valve prolapse syndrome. Folia Med Cracov 2000; 41(3-4): 17-24.
12. Pedersen HD, Haggstrom J. Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. Cardiovasc Res 2000; 47(2): 234-43.
13. Wroblewska-Kaluzewska M, Piorecka-Makula A, Tomik A. Arrhythmia and repolarization in children with mitral valve prolapse. Wiad Lek 2000; 53(9-10): 513-7.
Review
For citations:
Akatova E.V., Nikolin O.P., Martynov A.I. Clinical effectiveness of magnesium orotate in patients with cardiac arrhythmias, arterial hypertension, and mitral valve prolapse. Cardiovascular Therapy and Prevention. 2009;8(8):9-12. (In Russ.)
Views:
3882
Email this article 
